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V A L U E I N H E A L T H 1 7 ( 2 0 1 4 ) 3 0 2 – 3 0 6 305about health care options may require more explanation of the
questions and explanation of the intent.
This pilot study was limited to a small sample in certain
geographic areas. This study also excluded people with cognitive
impairment, which is common for LTC placement. Testing these
methods in a larger sample from other areas and further testing
their validity will be important if these techniques are to be used
more generally.
Despite these remaining challenges, the TTO technique seems a
feasible method to quantify preferences over LTC delivery options,
thus enabling a more quantitative assessment of their cost-
effectiveness. This study extends TTOmethods to health conditions
that include health care delivery modes. It therefore serves as a
proof of concept for using TTO methods to assess important policy
questions about allocating LTC resources more efﬁciently. These
methods may be applicable to various health care alternatives in
which better evidence is needed to guide funding policy.
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